Catalyst Pharmaceuticals, Inc. (CPRX)

16.02 -0.19 (-1.17%) At close: 04:00PM EDT

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 76

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Patrick J. McEnany	Co-Founder, Chairman, Pres & CEO	1.05M	N/A	1947
Ms. Alicia Grande C.M.A., CPA, CMA, CPA	Chief Accounting Officer, VP, Treasurer & CFO	617.94k	N/A	1971
Dr. Steven R. Miller Ph.D.	COO & Chief Scientific Officer	745.71k	N/A	1962
Dr. Gary Ingenito M.D., Ph.D.	Chief Medical & Regulatory Officer	706.86k	N/A	1956
Dr. Preethi Sundaram Ph.D.	Chief Strategy Officer	511.25k	N/A	1976
Ms. Mary Coleman	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Brian Elsbernd J.D.	Chief Compliance Officer & Chief Legal Officer	N/A	N/A	1964
Mr. Pete Curry Sr.	VP of Sales	N/A	N/A	N/A
Mr. Jeffrey Del Carmen	Chief Commercial Officer	N/A	N/A	1971
Mr. Philip B. Schwartz	Corp. Sec.	N/A	N/A	1955

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 5. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.